Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study

Preexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex with men (MSM) raises concerns about increased sexually transmitted infections (STIs). The Center for Disease Control and Prevention's (...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical infectious diseases Jg. 65; H. 5; S. 712
Hauptverfasser:	Jenness, Samuel M, Weiss, Kevin M, Goodreau, Steven M, Gift, Thomas, Chesson, Harrell, Hoover, Karen W, Smith, Dawn K, Liu, Albert Y, Sullivan, Patrick S, Rosenberg, Eli S
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.09.2017
Schlagworte:	Chlamydia Infections - epidemiology Cohort Studies Gonorrhea - epidemiology HIV Infections - epidemiology HIV Infections - prevention & control Homosexuality, Male Humans Male Models, Statistical Pre-Exposure Prophylaxis - methods Pre-Exposure Prophylaxis - statistics & numerical data mathematical model Chlamydia trachomatis Neisseria gonorrhoeae preexposure prophylaxis men who have sex with men
ISSN:	1537-6591, 1537-6591
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Preexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex with men (MSM) raises concerns about increased sexually transmitted infections (STIs). The Center for Disease Control and Prevention's (CDC's) PrEP guidelines recommend biannual STI screening, which may reduce incidence by treating STIs that would otherwise remain undiagnosed. We investigated these two counteracting phenomena. With a network-based mathematical model of HIV, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmission dynamics among MSM in the United States, we simulated PrEP uptake following the prescription indications and HIV/STI screening recommendations in the CDC guidelines. Scenarios varied PrEP coverage (the proportion of MSM indicated for PrEP who received it), RC (a reduction in the per-act probability of condom use), and the STI screening interval. In our reference scenario (40% coverage, 40% RC), 42% of NG and 40% of CT infections would be averted over the next decade. A doubling of RC would still result in net STI prevention relative to no PrEP. STIs declined because PrEP-related STI screening resulted in a 17% and 16% absolute increase in the treatment of asymptomatic and rectal STIs, respectively. Screening and timely treatment at quarterly vs biannual intervals would reduce STI incidence an additional 50%. Implementation of the CDC PrEP guidelines while scaling up PrEP coverage could result in a significant decline in STI incidence among MSM. Our study highlights the design of PrEP not only as antiretroviral medication but as combination HIV/STI prevention incorporating STI screening.
AbstractList	Preexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex with men (MSM) raises concerns about increased sexually transmitted infections (STIs). The Center for Disease Control and Prevention's (CDC's) PrEP guidelines recommend biannual STI screening, which may reduce incidence by treating STIs that would otherwise remain undiagnosed. We investigated these two counteracting phenomena.BackgroundPreexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex with men (MSM) raises concerns about increased sexually transmitted infections (STIs). The Center for Disease Control and Prevention's (CDC's) PrEP guidelines recommend biannual STI screening, which may reduce incidence by treating STIs that would otherwise remain undiagnosed. We investigated these two counteracting phenomena.With a network-based mathematical model of HIV, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmission dynamics among MSM in the United States, we simulated PrEP uptake following the prescription indications and HIV/STI screening recommendations in the CDC guidelines. Scenarios varied PrEP coverage (the proportion of MSM indicated for PrEP who received it), RC (a reduction in the per-act probability of condom use), and the STI screening interval.MethodsWith a network-based mathematical model of HIV, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmission dynamics among MSM in the United States, we simulated PrEP uptake following the prescription indications and HIV/STI screening recommendations in the CDC guidelines. Scenarios varied PrEP coverage (the proportion of MSM indicated for PrEP who received it), RC (a reduction in the per-act probability of condom use), and the STI screening interval.In our reference scenario (40% coverage, 40% RC), 42% of NG and 40% of CT infections would be averted over the next decade. A doubling of RC would still result in net STI prevention relative to no PrEP. STIs declined because PrEP-related STI screening resulted in a 17% and 16% absolute increase in the treatment of asymptomatic and rectal STIs, respectively. Screening and timely treatment at quarterly vs biannual intervals would reduce STI incidence an additional 50%.ResultsIn our reference scenario (40% coverage, 40% RC), 42% of NG and 40% of CT infections would be averted over the next decade. A doubling of RC would still result in net STI prevention relative to no PrEP. STIs declined because PrEP-related STI screening resulted in a 17% and 16% absolute increase in the treatment of asymptomatic and rectal STIs, respectively. Screening and timely treatment at quarterly vs biannual intervals would reduce STI incidence an additional 50%.Implementation of the CDC PrEP guidelines while scaling up PrEP coverage could result in a significant decline in STI incidence among MSM. Our study highlights the design of PrEP not only as antiretroviral medication but as combination HIV/STI prevention incorporating STI screening.ConclusionsImplementation of the CDC PrEP guidelines while scaling up PrEP coverage could result in a significant decline in STI incidence among MSM. Our study highlights the design of PrEP not only as antiretroviral medication but as combination HIV/STI prevention incorporating STI screening. Preexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex with men (MSM) raises concerns about increased sexually transmitted infections (STIs). The Center for Disease Control and Prevention's (CDC's) PrEP guidelines recommend biannual STI screening, which may reduce incidence by treating STIs that would otherwise remain undiagnosed. We investigated these two counteracting phenomena. With a network-based mathematical model of HIV, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmission dynamics among MSM in the United States, we simulated PrEP uptake following the prescription indications and HIV/STI screening recommendations in the CDC guidelines. Scenarios varied PrEP coverage (the proportion of MSM indicated for PrEP who received it), RC (a reduction in the per-act probability of condom use), and the STI screening interval. In our reference scenario (40% coverage, 40% RC), 42% of NG and 40% of CT infections would be averted over the next decade. A doubling of RC would still result in net STI prevention relative to no PrEP. STIs declined because PrEP-related STI screening resulted in a 17% and 16% absolute increase in the treatment of asymptomatic and rectal STIs, respectively. Screening and timely treatment at quarterly vs biannual intervals would reduce STI incidence an additional 50%. Implementation of the CDC PrEP guidelines while scaling up PrEP coverage could result in a significant decline in STI incidence among MSM. Our study highlights the design of PrEP not only as antiretroviral medication but as combination HIV/STI prevention incorporating STI screening.
Author	Sullivan, Patrick S Weiss, Kevin M Rosenberg, Eli S Chesson, Harrell Hoover, Karen W Goodreau, Steven M Smith, Dawn K Liu, Albert Y Jenness, Samuel M Gift, Thomas
Author_xml	– sequence: 1 givenname: Samuel M surname: Jenness fullname: Jenness, Samuel M organization: Department of Epidemiology, Emory University, Atlanta, Georgia – sequence: 2 givenname: Kevin M surname: Weiss fullname: Weiss, Kevin M organization: Department of Epidemiology, Emory University, Atlanta, Georgia – sequence: 3 givenname: Steven M surname: Goodreau fullname: Goodreau, Steven M organization: Department of Anthropology, University of Washington, Seattle – sequence: 4 givenname: Thomas surname: Gift fullname: Gift, Thomas organization: Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 5 givenname: Harrell surname: Chesson fullname: Chesson, Harrell organization: Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 6 givenname: Karen W surname: Hoover fullname: Hoover, Karen W organization: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 7 givenname: Dawn K surname: Smith fullname: Smith, Dawn K organization: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 8 givenname: Albert Y surname: Liu fullname: Liu, Albert Y organization: San Francisco Department of Public Health, California – sequence: 9 givenname: Patrick S surname: Sullivan fullname: Sullivan, Patrick S organization: Department of Epidemiology, Emory University, Atlanta, Georgia – sequence: 10 givenname: Eli S surname: Rosenberg fullname: Rosenberg, Eli S organization: Department of Epidemiology, Emory University, Atlanta, Georgia
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28505240$$D View this record in MEDLINE/PubMed
BookMark	eNpNkM1OwzAQhC0Eoj9w4QGQj1wCdmI3Dreqoj9SK5AK9Bg58ZoYJXaJG2gehPclFUXisNrRar4ZaQfo1DoLCF1RcktJEt3lRnWzZ1FygvqUR3Ew4gk9_ad7aOD9OyGUCsLPUS8UnPCQkT76XtgOB5sDdhrPnHV1XYDE0io8KUpZtcpIPHVl6b6MfcPzppIWL6qqsU6BNrnp2Ba_mrrx-KkG2G-db2rotNsWbSn3xuNx5Tp0BRZvCofn8hPwGvZ4Y3bF4XqPx3jVpZWHgvWuUe0FOtOy9HB53EP0Mn14nsyD5eNsMRkvg5yFYhdIprjQijDNYgpchUqqhCYiGxGREcKinFOIpYiAijzMhJYx0TmLGMR6JKkOh-jmN3dbu48G_C6tjM-hLKUF1_iUiiRhNIoZ76zXR2uTVaDSbW0qWbfp3yvDHxRGeT8
CitedBy_id	crossref_primary_10_1007_s15006_019_0185_5 crossref_primary_10_1136_sextrans_2025_056540 crossref_primary_10_1080_10618600_2023_2233593 crossref_primary_10_7326_M21_1548 crossref_primary_10_1097_QAI_0000000000002482 crossref_primary_10_1007_s00508_025_02499_6 crossref_primary_10_1016_j_dld_2018_05_021 crossref_primary_10_1186_s12879_024_09144_z crossref_primary_10_14423_SMJ_0000000000001564 crossref_primary_10_1093_cid_ciaa1033 crossref_primary_10_1177_09622802221146311 crossref_primary_10_1001_jamainternmed_2019_5456 crossref_primary_10_1097_OLQ_0000000000001043 crossref_primary_10_1002_jia2_25355 crossref_primary_10_1007_s10461_020_03105_8 crossref_primary_10_1097_OLQ_0000000000000870 crossref_primary_10_1097_QAD_0000000000002469 crossref_primary_10_1093_cid_ciz552 crossref_primary_10_1097_QAD_0000000000003676 crossref_primary_10_1177_09564624241233792 crossref_primary_10_1007_s10508_024_02922_5 crossref_primary_10_1080_00224499_2021_1936440 crossref_primary_10_1097_OLQ_0000000000001685 crossref_primary_10_1002_jia2_25351 crossref_primary_10_1097_JXX_0000000000000569 crossref_primary_10_1007_s15010_018_1127_3 crossref_primary_10_1371_journal_pntd_0011548 crossref_primary_10_1093_ofid_ofaf320 crossref_primary_10_1093_cid_ciac043 crossref_primary_10_1097_QAD_0000000000001939 crossref_primary_10_1016_S1473_3099_23_00356_0 crossref_primary_10_1136_sextrans_2020_054741 crossref_primary_10_1007_s10461_018_2285_0 crossref_primary_10_3390_ijerph18073582 crossref_primary_10_1097_QAD_0000000000001703 crossref_primary_10_1016_j_tmaid_2018_06_008 crossref_primary_10_1097_EDE_0000000000001390 crossref_primary_10_1001_jamanetworkopen_2019_17134 crossref_primary_10_3201_eid2407_172104 crossref_primary_10_1007_s15010_024_02261_6 crossref_primary_10_1080_13102818_2019_1659183 crossref_primary_10_1177_09564624231173728 crossref_primary_10_1007_s10508_024_02859_9 crossref_primary_10_1136_bmjopen_2019_032054 crossref_primary_10_1017_S0950268818000092 crossref_primary_10_1093_cid_ciy529 crossref_primary_10_1186_s44263_025_00125_1 crossref_primary_10_1080_10826084_2020_1823419 crossref_primary_10_1097_QAI_0000000000002582 crossref_primary_10_1177_09564624241239994 crossref_primary_10_14745_ccdr_v44i02a02 crossref_primary_10_1093_cid_ciae572 crossref_primary_10_1186_s13584_021_00500_x crossref_primary_10_1080_10510974_2020_1778053 crossref_primary_10_1097_OLQ_0000000000001189 crossref_primary_10_1136_sextrans_2022_055439 crossref_primary_10_3390_ijerph20032582 crossref_primary_10_1097_OLQ_0000000000001064 crossref_primary_10_1097_QAD_0000000000002522 crossref_primary_10_1016_j_jaad_2018_02_045 crossref_primary_10_1177_09564624211056749 crossref_primary_10_3389_fphar_2018_00799 crossref_primary_10_1016_j_amepre_2020_10_021 crossref_primary_10_1002_jia2_25370 crossref_primary_10_1186_s12879_020_4831_4 crossref_primary_10_1016_S2352_3018_20_30203_4 crossref_primary_10_1097_OLQ_0000000000000896 crossref_primary_10_1097_OLQ_0000000000001908 crossref_primary_10_12688_f1000research_17955_1 crossref_primary_10_1007_s15010_018_1124_6 crossref_primary_10_1177_00333549231208487 crossref_primary_10_12688_f1000research_17955_2 crossref_primary_10_3389_fpubh_2019_00154 crossref_primary_10_1093_ofid_ofy099 crossref_primary_10_1111_1467_9566_12967 crossref_primary_10_1093_ofid_ofad401 crossref_primary_10_1371_journal_pone_0293968 crossref_primary_10_1128_jcm_00211_21 crossref_primary_10_1016_j_medmal_2020_10_017 crossref_primary_10_1136_sextrans_2020_054681 crossref_primary_10_1016_j_ijid_2023_01_007 crossref_primary_10_1097_OLQ_0000000000001239 crossref_primary_10_1097_QAD_0000000000003187 crossref_primary_10_1097_QAI_0000000000001885 crossref_primary_10_1371_journal_pone_0208107 crossref_primary_10_1007_s10461_018_2332_x crossref_primary_10_1007_s10461_018_2252_9 crossref_primary_10_1097_QAD_0000000000004203 crossref_primary_10_1097_OLQ_0000000000001080 crossref_primary_10_1136_sextrans_2023_056103 crossref_primary_10_1007_s10461_018_2290_3 crossref_primary_10_1038_s41598_020_62694_5 crossref_primary_10_1007_s10508_022_02486_2 crossref_primary_10_1093_cid_ciz510 crossref_primary_10_1089_apc_2021_0219 crossref_primary_10_1007_s15006_019_0575_8 crossref_primary_10_1097_QCO_0000000000000621 crossref_primary_10_1186_s12889_023_15946_8 crossref_primary_10_1521_aeap_2018_30_5_393 crossref_primary_10_1097_QAD_0000000000003872 crossref_primary_10_1097_QAI_0000000000003015 crossref_primary_10_2105_AJPH_2017_304172 crossref_primary_10_1002_jia2_25673 crossref_primary_10_1186_s12916_020_01796_3 crossref_primary_10_1093_ofid_ofx185 crossref_primary_10_1097_OLQ_0000000000001649 crossref_primary_10_1521_aeap_2021_33_5_411 crossref_primary_10_1002_jia2_25826 crossref_primary_10_1071_SH17196 crossref_primary_10_1097_OLQ_0000000000001092 crossref_primary_10_1371_journal_pone_0217315 crossref_primary_10_3390_idr16030032 crossref_primary_10_1080_14787210_2025_2526846 crossref_primary_10_1038_s41598_022_07116_4 crossref_primary_10_1136_sextrans_2023_055922 crossref_primary_10_1089_apc_2018_0290 crossref_primary_10_1371_journal_pone_0248582 crossref_primary_10_1097_QAI_0000000000002719 crossref_primary_10_2105_AJPH_2018_304561 crossref_primary_10_1186_s12879_024_10310_6 crossref_primary_10_1093_ofid_ofz405 crossref_primary_10_1371_journal_pmed_1002485 crossref_primary_10_1136_sextrans_2023_056081 crossref_primary_10_1001_jama_2019_2945 crossref_primary_10_1016_j_epidem_2020_100386 crossref_primary_10_1016_S2352_3018_23_00299_0 crossref_primary_10_1001_jama_2019_2947 crossref_primary_10_1093_cid_cix873 crossref_primary_10_1111_ddg_15329_g crossref_primary_10_1093_cid_ciy048 crossref_primary_10_1177_09564624251325310 crossref_primary_10_1093_aje_kwy230 crossref_primary_10_1016_j_mcna_2023_08_014 crossref_primary_10_1097_QAI_0000000000001976 crossref_primary_10_1177_09564624231203363 crossref_primary_10_1016_S1473_3099_22_00284_5 crossref_primary_10_1089_apc_2022_0154 crossref_primary_10_15585_mmwr_rr7004a1 crossref_primary_10_1071_SH18131 crossref_primary_10_1080_13543776_2024_2367005 crossref_primary_10_1007_s10461_019_02664_9 crossref_primary_10_1097_QAI_0000000000002300 crossref_primary_10_1097_QAI_0000000000003511 crossref_primary_10_1111_hiv_13543 crossref_primary_10_1590_s1678_9946202163076 crossref_primary_10_1080_08824096_2020_1760815 crossref_primary_10_1177_2325958220919269 crossref_primary_10_1097_OLQ_0000000000001665 crossref_primary_10_1001_jamanetworkopen_2020_30806 crossref_primary_10_1097_QAD_0000000000002290 crossref_primary_10_1016_j_medcli_2019_10_007 crossref_primary_10_1093_cid_ciz1145 crossref_primary_10_1098_rspb_2025_1453 crossref_primary_10_1016_j_medcle_2019_10_006 crossref_primary_10_1093_ofid_ofad165 crossref_primary_10_1016_j_drugpo_2022_103628 crossref_primary_10_1016_j_cnur_2020_06_006 crossref_primary_10_1016_S1473_3099_22_00175_X crossref_primary_10_1186_s12889_020_09363_4 crossref_primary_10_1097_OLQ_0000000000001032 crossref_primary_10_1016_S2352_3018_19_30043_8 crossref_primary_10_1093_cid_ciy050 crossref_primary_10_1097_OLQ_0000000000000980 crossref_primary_10_1007_s11904_019_00446_5 crossref_primary_10_1007_s10508_021_02045_1 crossref_primary_10_1186_s12879_018_3600_0 crossref_primary_10_1177_09564624211053428 crossref_primary_10_1093_infdis_jiab051 crossref_primary_10_1002_jia2_25442 crossref_primary_10_47102_annals_acadmedsg_2024285 crossref_primary_10_1111_ddg_15329
ContentType	Journal Article
Copyright	The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Copyright_xml	– notice: The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/cid/cix439
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1537-6591
ExternalDocumentID	28505240
Genre	Journal Article
GrantInformation_xml	– fundername: NIMH NIH HHS grantid: R21 MH112449 – fundername: NIAID NIH HHS grantid: P30 AI050409 – fundername: NCHHSTP CDC HHS grantid: U38 PS004646 – fundername: NICHD NIH HHS grantid: R21 HD075662 – fundername: NIAID NIH HHS grantid: P30 AI027757
GroupedDBID	--- ..I .2P .I3 .ZR 08P 0R~ 1KJ 1TH 29B 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACHIC ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N9A NGC NOMLY NOYVH NPM NU- NVLIB O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- 7X8
ID	FETCH-LOGICAL-c428t-a4d58fd04f471e5d2dad9198b608b0043c51e7a83e18c2b8fa70fc434e7f6a1f2
IEDL.DBID	7X8
ISICitedReferencesCount	180
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000407808400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1537-6591
IngestDate	Wed Oct 01 13:53:23 EDT 2025 Thu Jul 03 03:53:01 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	mathematical model Chlamydia trachomatis Neisseria gonorrhoeae preexposure prophylaxis men who have sex with men
Language	English
License	The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c428t-a4d58fd04f471e5d2dad9198b608b0043c51e7a83e18c2b8fa70fc434e7f6a1f2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://academic.oup.com/cid/article-pdf/65/5/712/24266467/cix439.pdf
PMID	28505240
PQID	1899413745
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1899413745 pubmed_primary_28505240
PublicationCentury	2000
PublicationDate	2017-09-01
PublicationDateYYYYMMDD	2017-09-01
PublicationDate_xml	– month: 09 year: 2017 text: 2017-09-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical infectious diseases
PublicationTitleAlternate	Clin Infect Dis
PublicationYear	2017
References	29370356 - Clin Infect Dis. 2018 Jun 18;67(1):155-156. doi: 10.1093/cid/ciy050. 29370373 - Clin Infect Dis. 2018 Jun 18;67(1):154-155. doi: 10.1093/cid/ciy048.
References_xml	– reference: 29370356 - Clin Infect Dis. 2018 Jun 18;67(1):155-156. doi: 10.1093/cid/ciy050. – reference: 29370373 - Clin Infect Dis. 2018 Jun 18;67(1):154-155. doi: 10.1093/cid/ciy048.
SSID	ssj0011805
Score	2.6140003
Snippet	Preexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	712
SubjectTerms	Chlamydia Infections - epidemiology Cohort Studies Gonorrhea - epidemiology HIV Infections - epidemiology HIV Infections - prevention & control Homosexuality, Male Humans Male Models, Statistical Pre-Exposure Prophylaxis - methods Pre-Exposure Prophylaxis - statistics & numerical data
Title	Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study
URI	https://www.ncbi.nlm.nih.gov/pubmed/28505240 https://www.proquest.com/docview/1899413745
Volume	65
WOSCitedRecordID	wos000407808400008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Li9swEBZtt5Re-u52-2IKvYq1ZSmSeylh2XR7SAj0sbkFWRoRQ7Gydnab_SH9vx05Dnsrhb0YYxAYzWi-0bw-xj5WKqsI9hzPhVdcurzkFSEFR0fuMBICO7Q92YSezcxiUc6HgFs3lFXubWJvqH10KUZ-nNPFgAyulurz-oIn1qiUXR0oNO6yg4JcmVTSpRc3WYTc9CWMdKg1H6ky348nLYtjR6J29VYW_3Ate4iZPL7tzz1hjwbnEsY7bXjK7mDzjD2YDunz5-wPWYMdiSjEAF9iE9uWjDHYxsPJinTjmrQFJqQa8TdBGvQRfviaWkiixzRrIjVqws-6vexg3iJu1zFFGOk9krh-2W3dwTjRF8EUGzhfRTizVwjfcAvn9WaVvn6CMSQCttQGD6mK8foF-zE5_X5yxgdeBu7osrLhVnplgs9kIGRD5YW3vsxLU40yk6xA4VSO2poCc-NEZYLVWXCykKjDyOZBvGT3mtjgKwZCBI260CGoUmpMw-a084FQVVUOpThiH_YbviS9T8kM22C87JY3W37EDndSW653AzqWwiR6Ppm9_o_Vb9hDkZC6Lxt7yw4CnXp8x-67q03dte97haLnbD79Cwyc2FE
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+of+Gonorrhea+and+Chlamydia+Following+Human+Immunodeficiency+Virus+Preexposure+Prophylaxis+Among+Men+Who+Have+Sex+With+Men%3A+A+Modeling+Study&rft.jtitle=Clinical+infectious+diseases&rft.au=Jenness%2C+Samuel+M&rft.au=Weiss%2C+Kevin+M&rft.au=Goodreau%2C+Steven+M&rft.au=Gift%2C+Thomas&rft.date=2017-09-01&rft.eissn=1537-6591&rft.volume=65&rft.issue=5&rft.spage=712&rft_id=info:doi/10.1093%2Fcid%2Fcix439&rft_id=info%3Apmid%2F28505240&rft_id=info%3Apmid%2F28505240&rft.externalDocID=28505240
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon